2022 CADTH Information Session

Thursday, December 8, 2022

1:00 p.m. to 4:00 p.m. ET

Register

After registering, you will receive a confirmation email with information about how to join the webinar.

1:00 p.m. to 1:10 p.m.

Welcome

Suzanne McGurn, President and CEO, CADTH

1:10 p.m. to 1:40 p.m.

Pharmaceutical Reviews Portfolio

With a focus on the strategic pillars and guiding principles from the CADTH 2022–2025 Strategic Plan, the Pharmaceutical Reviews team will conduct a year in review for both manufacturer- and payer-initiated drug technology reviews.

Brent Fraser, Vice-President, Pharmaceutical Reviews, CADTH

Amanda Allard, Director, Pharmaceutical Reviews, CADTH

Peter Dyrda, Director, Pharmaceutical Policy and HTA, CADTH

1:40 p.m. to 2:10 p.m.

Medical Devices and Clinical Interventions Portfolio

The work of the Medical Devices and Clinical Interventions portfolio is being reshaped to better address the needs of decision-makers. This update will cover new approaches to address complex health technologies and complex information needs and to evaluate emerging technologies such as digital health.

Lesley Dunfield, Vice-President, Medical Devices and Clinical Interventions, CADTH

Laura Weeks, Director, HTA, CADTH

Joanne Kim, Manager, Clinical Research, CADTH

2:10 p.m. to 2:30 p.m.

Status Update on RWE at CADTH

An overview of initiatives to support the optimal integration of real-world evidence (RWE) into decision-making at CADTH by providing guidance on best practices for generating RWE in rare disease registries and reporting of RWE studies in submissions for HTAs and regulatory reviews.

Nicole Mittmann, Chief Scientist and Vice-President, Evidence Standards, CADTH

2:30 p.m. to 2:40 p.m.

Break

2:40 p.m. to 3:10 p.m.

Executive Strategy Update

This update will cover CADTH's approach to respectful engagement with First Nations, Inuit, and Métis peoples; initiatives to incorporate the principles of inclusion, diversity, equity, and access (IDEA) in CADTH's work; and the new Post-Market Drug Evaluation (PMDE) program that extends CADTH's services to cover the full life cycle of health technologies.

Heather Logan, Executive Strategy Lead, CADTH

Tarry Ahuja, Director, Post-Market Drug Evaluation, CADTH

3:10 p.m. to 3:30 p.m.

CADTH Myth Busting

CADTH's Executive Team discusses some of the common misconceptions about CADTH and its work.

3:30 p.m. to 3:50 p.m.

Open Forum

This is an opportunity for attendees to ask questions about the material presented during the session and broader questions about anything related to CADTH and the work done at CADTH.

3:50 p.m. to 4:00 p.m.

Closing Remarks

Suzanne McGurn, President and CEO, CADTH